Baxter International Inc (NYSE:BAX) has been assigned a consensus recommendation of “Buy” from the seventeen ratings firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $79.20.
BAX has been the subject of a number of analyst reports. Morgan Stanley increased their target price on Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 5th. Zacks Investment Research raised Baxter International from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research note on Tuesday, March 19th. Wells Fargo & Co increased their target price on Baxter International from $80.00 to $89.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 3rd. Barclays increased their target price on Baxter International from $72.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. Finally, Cowen set a $75.00 target price on Baxter International and gave the stock a “hold” rating in a research note on Monday, April 22nd.
Shares of BAX stock opened at $81.90 on Friday. The stock has a market cap of $41.78 billion, a P/E ratio of 26.85, a price-to-earnings-growth ratio of 1.90 and a beta of 0.94. The stock’s 50 day simple moving average is $77.30. Baxter International has a 12-month low of $61.05 and a 12-month high of $82.80. The company has a current ratio of 1.83, a quick ratio of 1.30 and a debt-to-equity ratio of 0.50.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Friday, June 7th will be paid a $0.22 dividend. This is an increase from Baxter International’s previous quarterly dividend of $0.19. This represents a $0.88 annualized dividend and a yield of 1.07%. The ex-dividend date is Thursday, June 6th. Baxter International’s dividend payout ratio (DPR) is presently 28.85%.
In other Baxter International news, Director Thomas T. Stallkamp sold 1,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $76.20, for a total transaction of $76,200.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Jacqueline Kunzler sold 593 shares of the stock in a transaction on Wednesday, June 19th. The shares were sold at an average price of $80.46, for a total value of $47,712.78. Following the sale, the senior vice president now owns 9,023 shares in the company, valued at approximately $725,990.58. The disclosure for this sale can be found here. Insiders sold a total of 5,008,593 shares of company stock valued at $382,542,285 over the last ninety days. 0.70% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the business. Weaver Consulting Group acquired a new stake in Baxter International during the 1st quarter valued at $25,000. Parisi Gray Wealth Management acquired a new stake in Baxter International during the 4th quarter valued at $26,000. C J Advisory Inc acquired a new stake in Baxter International during the 1st quarter valued at $28,000. Sontag Advisory LLC acquired a new stake in Baxter International during the 4th quarter valued at $30,000. Finally, Ellis Investment Partners LLC acquired a new stake in Baxter International during the 1st quarter valued at $36,000. Hedge funds and other institutional investors own 83.99% of the company’s stock.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.